Clinical Trial Update: Study of Aerosolized Liposomal 9-Nitro-20 (S)- Camptothecin (L9NC) [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating aerosolized liposomal 9-Nitro-20(S)-Camptothecin (L9NC) for lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Cancer

Drugs mentioned

• Liposomal 9-Nitro-20(S)-Camptothecin (L9NC) (Liposomal 9-Nitro-20(S)-Camptothecin)

Snippet

Sponsor: University of New Mexico | Conditions: Lung Diseases, Cancer | Phase 2 | Status: COMPLETED